Related Experiment Videos
Summary
Dynorphin (1-13) acts on kappa receptors in blood vessels, inhibiting norepinephrine release and causing vasodilation. This peptide shows selective binding and functional effects in vascular tissues, unlike other enkephalins.
Area of Science:
- Pharmacology
- Neuroscience
- Cardiovascular Research
Background:
- Opioid receptors, including kappa receptors, are present in vascular tissues.
- Dynorphin (1-13) is an endogenous opioid peptide with known central nervous system effects.
Purpose of the Study:
- To investigate the binding characteristics and functional effects of dynorphin (1-13) in rabbit and dog vascular tissues.
- To determine the receptor subtype involved in dynorphin (1-13) mediated vascular responses.
Main Methods:
- Radioligand binding assays using (3H)etorphine to determine KD and Bmax values.
- In vitro studies measuring inhibition of electrically stimulated vasoconstriction in isolated arteries.
- Assessment of the effects of dynorphin (1-13) on noradrenaline-induced vasoconstriction.
Main Results:
- Dynorphin (1-13) exhibited specific binding to vascular membrane preparations with a KD of 20 nM.
- Dynorphin (1-13) inhibited electrically induced vasoconstriction in rabbit ear and dog mesenteric arteries (IC50 values 53 nM and 510 nM, respectively).
- These effects were partially reversed by naloxone and were distinct from the actions of other enkephalins and dynorphin (1-13) on brain tissues.
Conclusions:
- Dynorphin (1-13) selectively binds to kappa receptors in blood vessels.
- The peptide inhibits norepinephrine release presynaptically, leading to vasodilation.
- Dynorphin (1-13) represents a potential therapeutic agent for conditions involving vascular tone regulation.